Heidelberg Pharma AG
XETRA:HPHA
Heidelberg Pharma AG
XETRA:HPHA
Price:
2.98 EUR
Market Closed
Updated:
May 6, 2024
Section:
Relative Value
The Relative Value of one
HPHA
stock under the Base Case scenario is
3.39
EUR.
Compared to the current market price of 2.98 EUR,
Heidelberg Pharma AG
is
Undervalued by 12%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
HPHA
Relative Value
Base Case
3.39
EUR
Undervaluation 12%
Valuation Multiples
Multiples Across Competitors
HPHA Competitors Multiples
Heidelberg Pharma AG Competitors
Heidelberg Pharma AG Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| DE |
|
Heidelberg Pharma AG
XETRA:HPHA
|
138.9m EUR | 14.1 | -6.8 | -5 | -4.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
285.6B USD | 5.3 | 59.3 | 12.9 | 19.6 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
159.7B USD | 5.7 | 23.8 | 17.3 | 26 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
104.4B USD | 8 | 26.4 | 17.8 | 19.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
103.6B USD | 10.5 | 28.6 | 22.9 | 24 | |
| AU |
|
CSL Ltd
ASX:CSL
|
133.1B AUD | 6.2 | 35.6 | 21.6 | 26.7 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
80.3B USD | 2.9 | 165.8 | 6.6 | 8.7 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
45.9B USD | 6.7 | -9.7 | -10.5 | -8.9 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
32.1B USD | 3.3 | 27.5 | 14.1 | 17.6 | |
| KR |
|
Celltrion Inc
KRX:068270
|
39.2T KRW | 18 | 73.1 | 44.7 | 61.6 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
